AMENDMENTS TO THE CLAIMS

1.-57. (Canceled)

58. (Currently amended) ~~The~~ A fully human monoclonal antibody, or binding fragment thereof, ~~of Claim 57, wherein the antibody further comprises~~ comprising a light chain comprising the amino acid sequence of SEQ ID NO: 72 and a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 74 and wherein said antibody or said binding fragment thereof binds to human Tumor Necrosis Factor-α.

59.-60. (Canceled)

61. (Currently amended) A composition comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim ~~57~~ 58,~~wherein the antibody is in association with~~ and a pharmaceutically acceptable carrier.

62. (Canceled)

63. (Currently amended) A conjugate comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim ~~57~~ 58,~~wherein said antibody is conjugated to~~ and a therapeutic agent.

64. (Currently amended) The ~~antibody, or binding fragment thereof,~~ conjugate of Claim 63, wherein the therapeutic agent is a toxin.

65. (Currently amended) The ~~antibody, or binding fragment thereof,~~ conjugate of Claim 63, wherein the therapeutic agent is a radioisotope.

66. (Currently amended) ~~The~~ A fully human monoclonal antibody, or binding fragment thereof, ~~of Claim 57, wherein the antibody further comprises~~ comprising a light chain comprising the amino acid sequence of SEQ ID NO: 72 and a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 70 and wherein said antibody or said binding fragment thereof binds to human Tumor Necrosis Factor-α.

67.-68. (Canceled)

69. (Currently amended) A composition comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim 66~~, wherein the antibody is in association with~~ and a pharmaceutically acceptable carrier.

70.-72. (Canceled)

73. (Currently amended) ~~The~~ A fully human monoclonal antibody, or binding fragment thereof, ~~of Claim 57, wherein the antibody further comprises~~ comprising a light chain

comprising the amino acid sequence of SEQ ID NO: 50 and a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 52 and wherein said antibody or said binding fragment thereof binds to human Tumor Necrosis Factor-α.

74.-75. (Canceled)

76. (Currently amended) A composition comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim ~~72~~ 73~~, wherein the antibody is in association with~~ and a pharmaceutically acceptable carrier.

77. (Canceled)

78. (Currently amended) A conjugate comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim ~~72~~ 73~~, wherein said antibody is conjugated to~~ and a therapeutic agent.

79. (Currently amended) The ~~antibody, or binding fragment thereof,~~ conjugate of Claim 78, wherein the therapeutic agent is a toxin.

80. (Currently amended) The ~~antibody, or binding fragment thereof,~~ conjugate of Claim 78, wherein the therapeutic agent is a radioisotope.

81.-82. (Canceled)

83. (Currently amended) ~~The~~ A fully human monoclonal antibody, or binding fragment thereof, ~~of Claim 57, wherein the antibody further comprises~~ comprising a light chain comprising the amino acid sequence of SEQ ID NO: 54 and a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 56 and wherein said antibody or said binding fragment thereof binds to human Tumor Necrosis Factor-α.

84.-85. (Canceled)

86. (Currently amended) A composition comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim ~~82~~ 83~~, wherein the antibody is in association with~~ and a pharmaceutically acceptable carrier.

87. (Canceled)

88. (Currently amended) A conjugate comprising the ~~The~~ antibody~~,~~ or binding fragment ~~thereof,~~ of Claim ~~82~~ 83~~, wherein said antibody is conjugated to~~ and a therapeutic agent.

89. (Currently amended) The ~~antibody, or binding fragment thereof,~~ conjugate of Claim 88, wherein the therapeutic agent is a toxin.

90. (Currently amended) The ~~antibody, or binding fragment thereof,~~ conjugate of Claim 88, wherein the therapeutic agent is a radioisotope.

91.-106.(Canceled)

107. (New) A conjugate comprising the antibody or binding fragment of Claim 66 and a therapeutic agent.

108. (New) The conjugate of Claim 107, wherein the therapeutic agent comprises a toxin.

109. (New) The conjugate of Claim 107, wherein the therapeutic agent comprises a radioisotope.

110. (New) The binding fragment of Claim 66, wherein said binding fragment comprises a Fab, Fab', $F(ab')_2$, or Fv fragment.

111. (New) The antibody of Claim 66, wherein said antibody has an IgG2 isotype.

112. (New) The binding fragment of Claim 58, wherein said binding fragment comprises a Fab, Fab', $F(ab')_2$, or Fv fragment.

113. (New) The antibody of Claim 58, wherein said antibody has an IgG2 isotype.

114. (New) The binding fragment of Claim 73, wherein said binding fragment comprises a Fab, Fab', $F(ab')_2$, or Fv fragment.

115. (New) The antibody of Claim 73, wherein said antibody has an IgG2 isotype.

116. (New) The binding fragment of Claim 83, wherein said binding fragment comprises a Fab, Fab', $F(ab')_2$, or Fv fragment.

117. (New) The antibody of Claim 83, wherein said antibody has an IgG2 isotype.

118. (New) A fully human monoclonal antibody, or binding fragment thereof, that binds to Tumor Necrosis Factor-α, wherein the antibody, or binding fragment thereof, comprises:

a heavy chain complementarity determining region 1 (CDR1) having the amino acid sequence of "Ser Tyr Asp Met His" (SEQ ID NO: 321);

a heavy chain complementarity determining region 2 (CDR2) having the amino acid sequence of "Val Ile Trp Ser Asp Gly Ser Ile Lys Tyr Tyr Ala Asp Ser Val Lys Gly" (SEQ ID NO: 322);

a heavy chain complementarity determining region 3 (CDR3) having the amino acid sequence of "Glu Val Glu Ser Ala Met Gly Gly Phe Tyr Tyr Asn Gly Met Asp Val" (SEQ ID NO: 323);

a light chain complementarity determining region 1 (CDR1) having the amino acid sequence of "Arg Ala Ser Gln Gly Ile Arg Ile Asp Leu Gly" (SEQ ID NO: 324);

a light chain complementarity determining region 2 (CDR2) having the amino acid sequence of "Ala Ala Ser Thr Leu Gln Ser" (SEQ ID NO: 325); and

a light chain complementarity determining region 3 (CDR3) having the amino acid sequence of "Leu Gln His Lys Ser Tyr Pro Leu Thr" (SEQ ID NO: 326).

119. (New) The antibody, or binding fragment thereof, of Claim 118, wherein the antibody, or binding fragment thereof, comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 70 and a light chain polypeptide having the amino acid sequence of SEQ ID NO: 72.

120. (New) The antibody, or binding fragment thereof, of Claim 118, wherein the antibody, or binding fragment thereof, comprises a heavy chain polypeptide having the amino acid sequence of SEQ ID NO: 74 and a light chain polypeptide having the amino acid sequence of SEQ ID NO: 72.

121. (New) The binding fragment of Claim 118, wherein said binding fragment comprises a Fab, Fab', $F(ab')_2$, or Fv fragment.

122. (New) The antibody of Claim 118, wherein said antibody has an IgG2 isotype.

123. (New) A composition comprising the antibody or binding fragment of Claim 122, and a pharmaceutically acceptable carrier.

124. (New) A conjugate comprising the antibody or binding fragment of Claim 122, and a therapeutic agent.

125. (New) The conjugate of Claim 124, wherein the therapeutic agent is a toxin.

126. (New) The conjugate of Claim 124, wherein the therapeutic agent is a radioisotope.

127. (New) The conjugate according to Claim 63, 78, 88, 107 or 124, admixed with a pharmaceutically acceptable carrier.